Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Bicycle Therapeutics (Group)

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA. *


Period Start 2009-10-06 splitoff
  Today Bicycle Therapeutics Ltd.
  Predecessor MRC (GB), Laboratory of Molecular Biology (MRC-LMB, Cambridge)
Products Industry Bicycle Drug Conjugates®
  Industry 2 phage display technology
Persons Person Lee, Kevin (Bicycle Therapeutics 201509– CEO before Pfizer + GSK)
  Person 2 Winter, Gregory (MRC + CAT + Domantis + Nobel Laureate)
Region Region Cambridge, Cambridgeshire
  Country United Kingdom (GB)
  Street Blocks A & B Portway Building
Granta Park, Great Abington
  City CB21 6GP Cambridge, Cambridgeshire
    Address record changed: 2024-01-05
Basic data Employees D: 101 to 500 (2023-12-31)
  Currency USD
  Annual sales 25,859,000 (revenue, consolidated (2023) 2023-12-31)
  Profit -168,578,000 (2023-12-31)
  Cash 526,423,000 (2023-12-31)
    * Document for »About Section«: Bicycle Therapeutics plc. (6/23/23). "Press Release: Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer". Cambridge & Boston, MA.
Record changed: 2024-05-23


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Bicycle Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top